Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Reistone Biopharma Company Limited

http://www.reistonebio.com/

Latest From Reistone Biopharma Company Limited

Incyte Taps Wide-Open Vitiligo Market With Positive Ruxolitinib Results

Dermatologists have compared the current market for vitiligo to that of psoriasis 30 years ago, which grew from one with a dearth of therapies to one worth about $8bn.

Dermatology Immune Disorders

Patient-Focused Meeting On Vitiligo Could Galvanize R&D As The First Drug Candidates In A Long Time Advance

US FDA meeting directs attention to the vitiligo patient experience as a small group of potential treatments, led by topical Janus kinase inhibitors, are at the Phase II hinge point.

Research & Development Dermatology

Turkey's Abdi Ibrahim Beats Multinationals On Domestic Pharma Market

The Turkish pharmaceutical market reached $5.6bn in 2017. Despite strong competition from multinationals, Abdi Ibrahim, a local company, was market leader last year with a turnover of $380m. It was followed by Novartis and Pfizer.

Turkey Market Intelligence

Takeda’s Planned Emerging Markets Deal: India Yay Or Nay?

Takeda tantalizingly disclosed during its third quarter results that it has set aside funds for an acquisition worth around $450m in an undisclosed emerging market. What are the likely targets?

Emerging Markets Deals
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
UsernamePublicRestriction

Register